Nancy A. Melville PHOENIX — Early responders to zilucoplan, the newly approved medication for myasthenia gravis (MG), have sustained benefit for up to 60 weeks, new analyses show. “The information [in the studies] is valuable in making clinical decisions in managing MG, which is a chronic autoimmune condition that requires long-term use of immunosuppressives,” Xinli...
Tag: <span>myasthenia gravis drug</span>
Post
Researchers suggest myasthenia gravis drug be tested for use in post-COVID-19 patients
by Compuscript Ltd Credit: Unsplash/CC0 Public Domain A significant proportion of patients who survive COVID-19 develop a constellation of life-altering symptoms that persist long after the initial infection has resolved. This post-COVID-19 syndrome may result from the development of autoreactive IgG antibodies that cause inflammation and tissue injury. The authors of a new article published...